Article
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Oncotarget - 13 Jun 2017
Groisberg Roman, Hong David S, Holla Vijaykumar, Janku Filip, Piha-Paul Sarina, Ravi Vinod, Benjamin Robert, Kumar Patel Shreyas, Somaiah Neeta, Conley Anthony, Ali Siraj M, Schrock Alexa B, Ross Jeffrey S, Stephens Philip J, Miller Vincent A, Sen Shiraj, Herzog Cynthia, Meric-Bernstam Funda, Subbiah Vivek
Abstract excerpt
BACKGROUND: There are currently no United States Food and Drug Administration approved molecularly matched therapies for sarcomas except gastrointestinal stromal tumors. Complicating this is the extreme diversity, heterogeneity, and rarity of these neoplasms. Few therapeutic options exist for relapsed and refractory sarcomas. In clinical practice many oncologists refer patients for genomic profiling hoping for...
Topics
Join the communities discussing this publication.